Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for cardiac function and ventricular remodeling in acute coronary syndrome with type 2 diabetes
ChiCTR2400091911Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide in acute coronary syndrome (ACS), type 2 diabetes mellitus (T2DM), left ventricular dysfunction and 1 more (2 arms), sponsored by Beijing Hospital. Primary endpoints: NT-proBNP at 6 months and Global longitudinal strain at 6 months. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
03
Conditions
acute coronary syndrome (ACS)type 2 diabetes mellitus (T2DM)left ventricular dysfunctioncardiac remodeling
Beyond the preview
Go deeper on ChiCTR2400091911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091911.